Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Compugen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Compugen Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Neviah Genomics Raises Additional Funds through Venture Financing 12
Partnerships 13
Compugen Enters into Research Agreement with Mount Sinai Innovation Partners 13
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 14
BioLineRx Enters Into Co-Development Agreement With Compugen 15
Compugen Enters Into Co-Marketing Agreement With DiscoveRx 16
Licensing Agreements 17
Compugen Enters into Licensing Agreement with Bayer HealthCare for Cancer Immunotherapies 17
Equity Offering 18
Compugen Completes Public Offering Of Shares For US$72.5 Million 18
Evogene Completes Public Offering Of Shares For US$84.8 Million 19
Keddem Bioscience Announces Private Placement Of Common Stock For US$15 Million 20
Compugen Announces Private Placement Of Shares For US$8 Million 21
Compugen Files Registration Statement For Public Offering Of Common Stock For US$40 Million 22
Compugen Ltd – Key Competitors 23
Compugen Ltd – Key Employees 24
Compugen Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Affiliate 25
Joint Venture 26
Recent Developments 27
Financial Announcements 27
Nov 07, 2017: Compugen Reports Third Quarter 2017 Results 27
Aug 02, 2017: Compugen Reports Second Quarter 2017 Results 28
May 09, 2017: Compugen Reports First Quarter 2017 Results 29
Feb 15, 2017: Compugen Reports Fourth Quarter and Calendar Year 2016 Results 30
Nov 07, 2016: Compugen Reports 3rd Quarter 2016 Financial Results 31
Aug 02, 2016: Compugen Reports 2nd Quarter 2016 Financial Results 32
May 10, 2016: Compugen Reports First Quarter 2016 Financial Results 33
Feb 09, 2016: Compugen Reports Fourth Quarter and Calendar 2015 Results 34
Corporate Communications 35
Aug 02, 2017: Compugen Welcomes Paul Sekhri as its New Chairman of the Board 35
Mar 08, 2017: Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board 36
Product News 37
Oct 09, 2017: A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy 37
Aug 30, 2016: Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy 38
07/26/2017: Compugen Provides Update on its Cancer Drug Candidate CGEN-15022 39
06/22/2016: Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program 40
03/28/2017: Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program 41
03/02/2017: Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR 42
02/29/2016: Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program 43
01/04/2017: Compugen’s CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity 44
Clinical Trials 45
May 04, 2017: Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO 45
Dec 07, 2016: Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint 46
Nov 11, 2016: Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments 47
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
Compugen Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Compugen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Neviah Genomics Raises Additional Funds through Venture Financing 12
Compugen Enters into Research Agreement with Mount Sinai Innovation Partners 13
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 14
BioLineRx Enters Into Co-Development Agreement With Compugen 15
Compugen Enters Into Co-Marketing Agreement With DiscoveRx 16
Compugen Enters into Licensing Agreement with Bayer HealthCare for Cancer Immunotherapies 17
Compugen Completes Public Offering Of Shares For US$72.5 Million 18
Evogene Completes Public Offering Of Shares For US$84.8 Million 19
Keddem Bioscience Announces Private Placement Of Common Stock For US$15 Million 20
Compugen Announces Private Placement Of Shares For US$8 Million 21
Compugen Files Registration Statement For Public Offering Of Common Stock For US$40 Million 22
Compugen Ltd, Key Competitors 23
Compugen Ltd, Key Employees 24
Compugen Ltd, Subsidiaries 25
Compugen Ltd, Affiliate 25
Compugen Ltd, Joint Venture 26